Sure to be released here at the 2023 Pediatric Neuro-Oncology...

Sure to be released here at the 2023 Pediatric Neuro-Oncology Research Conference - the promised interim data from Paxalisib - in that combination PNOC study. The company continues to say 1st half 2023 and even Dr Matt Dun has alluded to data being released soon, for this study that he has been so much a part of.

Matt Dun has used SNO Conferences to present in the past. No details of abstracts yet - but extremely likely PNOC will take the opportunity to present at this conference.

Such is the nature of this cancer - the presentation of data, could involve results of many dozens of patients. NOTE the short periods of time for results, of outcome measures (post initial radiation treatments).

----------------------------------------------------------------
Brief Summary:
This phase II trial determines if the combination of ONC201 with different drugs, panobinostat or paxalisib, is effective for treating patients with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes for patients with DMGs, and there are few treatment options. ONC201, panobinostat, and paxalisib are all enzyme inhibitors that may stop the growth of tumor cells by clocking some of the enzymes needed for cell growth. This phase II trial assesses different combinations of these drugs for the treatment of DMGs.

Primary Outcome Measures :

1. Progression-free survival at 6 months (PFS6) - Cohorts 1A, 1B, 2A, 2B Only [ Time Frame: 6 months after administration of ONC201 in the maintenance phase ]
   
2. Overall survival at 7 months (OS7) - Cohort 3A & 3B Only [ Time Frame: 7 months after administration of ONC201 in the maintenance phase ]
   

--------------------------------------------
Associate Professor Matt Dun presents at the Society of Neuro-Oncology (SNO) Annual Meeting 2022

-------------------------------------------------------------------------------------------------------------------------


This is going to be real data - in what may be 100 or more young patients.

See Rinnekin words from his post of 9 Feb 2023. (at very bottom). I agree - says it all, as to how important this interim data will be for paxalisib and the company - and its soon. This time finally......
WITHOUT THE OVERHAND OF A FUND RAISING (Company has about $8m).
---------------------------------------------------------------------------------
2023 Pediatric Neuro-Oncology Research Conference
June 22-24, 2023
Capital Hilton, Washington DC

The SNO 7th Biennial Pediatric Neuro-Oncology Research Conference will be held June 22-24, 2023, in Washington, D.C. at the Capital Hilton.

Building on the success of our previous pediatric meetings, this biennial conference encourages the sharing of ideas and results, new collaborations and offers attendees a state-of-the-art update in the field of pediatric brain tumor research. The scientific program will offer outstanding keynotes, panel discussions and abstract presentations on a range of timely themes shaping the future of pediatric neuro-oncology.


----------------------
Rinnekin 09/02/23
Talking about DIPG, the latest interview with JG in * was promising in my view when he said:
"We’ll have to look at the data and talk to agencies like the US FDA and the TGA here in Australia – but they are generally open to having these discussions,”
.......
It indicates to me that regulatory discussions on paxalisib in DIPG can happen far sooner than at the end of the combo DIPG trial.